June 17, 2013
Merus Presents Preclinical Data on its Novel Bispecific Antibody MCLA-117 at EHA 2013

May 27, 2013
SUPPRESTEM Consortium Led by Merus Receives €6 Million FP7 Grant from the European Union





Aglaia identifies groundbreaking opportunities in cancer research and, in close partnerships with inventors and entrepreneurs, takes these opportunities to the next phase of technical and commercial development.

In its commitment to create and build biomedical companies in the field of oncology, Aglaia does not only provide the financial means but also takes an active role in strategic and operational processes.

Aglaia Biomedical Ventures B.V. currently has two investment funds under management: Aglaia Oncology Fund B.V.and Aglaia Oncology Seed Fund B.V.